ArticleFood science & nutrition2025
The Effects of Wuniuzao Green Tea on Mice With High-Fat Diet-Induced Liver Steatosis.
Article in Food science & nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Effects of Wuniuzao Green Tea on Mice With High-Fat Diet-Induced Liver Steatosis.Food science & nutrition · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Wuniuzao is a famous Chinese tea with a history of more than 300 years. It is suitable for bulk production with excellent quality. Most current studies have focused on the cultivation, aroma compounds, and antioxidant capacity of Wuniuzao tea. However, the biological effects of Wuniuzao green tea water (WGT) extract on the prevention of high-fat diet (HFD)-induced liver steatosis and modulation of the intestinal microbiota have not yet been reported. This study was conducted to fill these gaps. Mice were divided into four groups and fed a normal diet, HFD, HFD + atorvastatin (10 mg/kg, positive control), and HFD + WGT (300 mg/kg), respectively. Nine-week administration of WGT reduced body weight, lipid accumulation, and serum lipid levels in HFD-fed mice. Liver function and serum glucose tolerance were improved, and hepatic steatosis was inhibited in the WGT group. Moreover, WGT treatment activated the AMPK signaling pathway, suggesting a mechanism for its effect on hepatic steatosis. WGT supplementation also increased intestinal microbiota diversity and modulated the ratio of Firmicutes to Bacteroidetes. WGT significantly alleviated HFD-induced liver steatosis and modulated HFD-induced intestinal microbial dysbiosis, suggesting its potential as a dietary supplement against HFD-induced obesity and associated liver steatosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.